The purpose of this study is to evaluate several investigational treatments for newly diagnosed or recurrent brain tumor to determine if any of these investigational treatments improve overall survival compared to standard of care treatments.
Aim of the study
The aim of the study is to evaluate several investigational treatments for newly diagnosed or recurrent brain cancer to determine whether any of these investigational treatments improve overall survival compared to standard treatments. "Under investigation" means that they are new treatments, sometimes referred to as "investigational products or study treatments", that have not yet been approved by Swissmedic for use in your type of cancer. The treatments being tested in this study were previously tested in humans. This means that there are already other studies conducted on humans in which the same investigational drugs were tested, so this study is not the first of its kind. The treatments have been tested on humans before and information and findings about their effect on study patients have been collected.
Who can take part?
Patients with newly diagnosed and recurrent glioblastoma (GBM AGILE)
Procedure
You are being asked to undergo a preliminary examination in order to participate in this clinical trial because you may have brain cancer (a newly diagnosed glioblastoma) or your brain tumor has returned (recurrent glioblastoma). The duration of your participation in the pre-trial section of this study is up to 28 days. You will be randomly assigned to your study treatment during the pre-trial phase of the study. At this point, you will be asked whether you are interested in participating in the treatment section of the study. Your investigator will explain which treatment you have been randomly assigned to and you will be asked to sign a separate patient information and consent form for the treatment portion of the study.
Compensation
None
Original study name
Global Adaptive Trial Master Protocol: An international, seamless phase II/III trial with adaptive randomization platform to evaluate multiple therapies in newly diagnosed and recurrent GBM
BASEC number
2021-01184
Financial support from
Global Coalition for Adaptive Research (GCAR)